Investigational drug · Phase 3
JZP926
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Juvenile Myoclonic Epilepsy.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
5
Any phase or sponsor naming "JZP926"
First trial start
2026
Sep 18, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "JZP926", any sponsor or status.
Conditions studied
As listed on its trial records.
- Juvenile Myoclonic Epilepsy
Approved drugs for the same conditions: Epilepsy and seizures · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "JZP926" as an intervention, largest first.
- A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic EpilepsyPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723963 · 260 participants (planned) · Start Sep 18, 2026 · Primary completion Aug 1, 2028
Drug: JZP926 capsule; Placebo · For: Juvenile Myoclonic Epilepsy
Sites: Phoenix, Arizona; Los Angeles, California; Sacramento, California · 23 sites in all
- A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEEPivotal-lookingRecruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07723976 · 120 participants (planned) · Start Oct 30, 2026 · Primary completion Sep 4, 2029
Drug: CBD-OS; Placebo · For: Developmental and Epileptic Encephalopathy (DEE)
Sites: Birmingham, Alabama; Phoenix, Arizona; Orange, California · 43 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07233239 · 100 participants (planned) · Start Nov 26, 2025 · Primary completion Nov 29, 2027
Drug: CBD-OS · For: Focal Seizures
Sites: Phoenix, Arizona; La Jolla, California; New Haven, Connecticut · 24 sites in all
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT05864846 · 79 participants · Start Jun 29, 2023 · Primary completion Apr 6, 2026
Drug: Cannabidiol Oral Solution [Epidiolex] · For: Tuberous Sclerosis Complex Associated Neuropsychiatric Disease
Sites: Aurora, Colorado; New Haven, Connecticut; Gainesville, Florida · 19 sites in all
- A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGSNot yet recruiting
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
NCT07728097 · 40 participants (planned) · Start Nov 18, 2026 · Primary completion Dec 28, 2028
Drug: Cannabidiol Oral Solution · For: Lennox-Gastaut Syndrome
Sites: Fresno, California; New Orleans, Louisiana; Raleigh, North Carolina
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Jazz Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.